Target intelligence / Profile preview

Heat-labile enterotoxin B subunit (LT-B)

Target
LT-B
Molecular classification
Bacterial toxin subunit, Lectin, Protein, Adjuvant
01

Overview

The heat-labile enterotoxin B subunit (LT-B) is the pentameric, non-enzymatic component of the heat-labile enterotoxin (LT) secreted by enterotoxigenic Escherichia coli (ETEC) (UniProt: P06717). Its primary biological function is to recognize and bind with high affinity to GM1 ganglioside receptors on the surface of intestinal epithelial cells, which triggers the endocytosis of the entire toxin complex. Once internalized, the associated A subunit disrupts cellular signaling, leading to the massive fluid loss characteristic of traveler's diarrhea (StatPearls: NBK482100). Because LT-B is essential for toxin entry and is highly immunogenic, it serves as a major target for the development of vaccines against ETEC infections. Beyond its role as a target, LT-B is extensively studied as a mucosal adjuvant because it can significantly enhance the systemic and mucosal immune response to co-administered antigens. Clinical applications include its use in oral vaccine formulations, such as the cross-protective effects seen with the cholera vaccine Dukoral, where it induces neutralizing antibodies that block the toxin's ability to bind to host cells (EMA: Dukoral Summary). However, its use as an adjuvant has faced challenges, such as the risk of Bell's palsy when administered via the intranasal route, necessitating the development of detoxified derivatives.

Other names
LTBHeat-labile enterotoxin subunit BEscherichia coli heat-labile enterotoxin B subunitLT-B subuniteltB
02

Mechanism of action

Vaccines targeting the LT-B subunit induce neutralizing antibodies (IgA and IgG) that bind to the B-subunit pentamer, sterically hindering its interaction with host GM1 ganglioside receptors and preventing toxin internalization (, 15507211).

03

Biological functions

Cell adhesionReceptor bindingEndocytosisImmune responseImmunomodulation
04

Disease associations

InfectionTraveler's diarrhea
05

Safety considerations

Risk of Bell's palsy with intranasal administrationPotential for mucosal inflammationCross-reactivity with endogenous gangliosides
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

Anti-LTB IgG antibody titersAnti-LTB IgA antibody titers

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Heat-labile enterotoxin B subunit (LT-B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heat-labile enterotoxin B subunit (LT-B).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call